LABT
NASDAQ HealthcareLakewood-Amedex Biotherapeutics Inc. - Common Stock
Biotechnology
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents that fight infections by disrupting microbial membranes. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
๐ Market Data
| Price | $3.43 |
|---|---|
| Volume | 45,759,487 |
| Market Cap | 48.08M |
| 52-Week High | $9.82 |
| 52-Week Low | $2.58 |
๐ฏ Investment Strategy Scores
LABT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (62/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find LABT in your text
Paste any article, transcript, or post โ the tool will extract LABT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.